Tin tức & Cập nhật
Lọc theo Chuyên ngành:
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
10 Mar 2023
Gene links breast cancer to stress, circadian disruption
Two researchers from the Philippines have discovered a gene the connects breast cancer development to stress and body clock disruption. In a recent study, they have shown the mechanism behind hormone and circadian regulation of the tumour-suppressor gene, Krüppel-like factor 9 (KLF9), and its effect on breast cancer progression.
Gene links breast cancer to stress, circadian disruption
09 Mar 2023
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
Patients with bladder cancer who underwent radical cystectomy may benefit from the use of smartphones and wearable technology to monitor their symptoms as well as biometric data, according to a recent study.
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
08 Mar 2023
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
08 Mar 2023
Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis
For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.
Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis
08 Mar 2023
Local plus systemic therapies improve survival in HCC
Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.
Local plus systemic therapies improve survival in HCC
07 Mar 2023
Darolutamide-containing triplet regimen ups survival in mHSPC regardless of disease volume, risk
In a post hoc analysis of the phase III ARASENS study, the triplet regimen comprising darolutamide, androgen deprivation therapy (ADT), and docetaxel continued to show overall survival (OS) benefit for metastatic hormone-sensitive prostate cancer (mHSPC) irrespective of disease volume and risk.